Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q86U70
UPID:
LDB1_HUMAN
Alternative names:
Carboxyl-terminal LIM domain-binding protein 2; LIM domain-binding factor CLIM2; Nuclear LIM interactor
Alternative UPACC:
Q86U70; B4DUC4; O75479; O96010; Q1EQX1; Q9UGM4
Background:
LIM domain-binding protein 1, also known as Carboxyl-terminal LIM domain-binding protein 2, LIM domain-binding factor CLIM2, and Nuclear LIM interactor, plays a pivotal role in cellular processes. It binds to the LIM domain of various transcription factors, influencing their transcriptional activity. This protein is crucial in the development of interneurons and motor neurons, working alongside LHX3 and ISL1. It also collaborates with LHX1/LIM1 in axis formation and gene expression activation, and with LMO2 in the regulation of red blood cell development.
Therapeutic significance:
Understanding the role of LIM domain-binding protein 1 could open doors to potential therapeutic strategies.